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Endometrioma: early detectionObjective. While a certain fraction of endometriomas can develop de novo epithelial ovarian cancer (EOC)
such as clear cell carcinoma (OCCC), there is currently no useful biomarker available for early detection of
OCCC from endometriomas. The aim of this study was to describe the diagnostic utility of a novel biomarker
for EOC especially for OCCC to distinguish from endometrioma.
Methods.More than 100,000 glycan structures of serum glycoproteins obtained from 134 pretreatment all
stage EOC patients (including 45 OCCCs) and 159 non-cancer control women (including 36 endometriomas)
were explored for a mass spectrum approach. Diagnostic accuracy of identiﬁed biomarker was compared to
the one of CA-125 by comparing area under curve (AUC) and positive/negative predictive values (PPV and NPV).
Results. A2160, a fully-sialylated alpha-chain of complement 4-binding protein, was identiﬁed as a candidate
targetmarker. A2160was signiﬁcantly elevated in all stages of OCCC compared towith endometriomas. Diagnos-
tic accuracy of A2160 (cutoff 1.6 U/mL) to distinguish early stage OCCC fromendometrioma is signiﬁcantly higher
than that of CA-125 (cutoff 35 IU/L): AUC for A2160 versus CA-125, 0.92 versus 0.67; PPV 95% versus 64%; and
NPV 85% versus 58%. In addition, fully-sialylated glycans had a higher accuracy for diagnosing EOC as compared
to partially-sialylated glycans of alpha-chain of complement 4-binding protein.
Conclusion. Our study suggested that A2160may be a useful biomarker to distinguish early-stage OCCC from
endometrioma. This new biomarker can be potentially applied for the monitoring of endometrioma patients,
making possible the early diagnosis of OCCC.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).d Gynecology, Tokai University
1193, Japan.
ami).
. This is an open access article under1. Introduction
Epithelial ovarian cancer (EOC) remains the leading cause of death
among the gynecological cancers in the United States [1]. Accurate diag-
nosis and early detection of EOC is always challenging, and only 15% of
EOC patients are diagnosed with early-stage disease. The remaining
large fraction of EOC patients are at an advanced-stage at the time ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of patients.
Participants Samples Age
Ovarian cancer Serous 30 56.8 +/-12.5
Clear cell 45 134
Endometrioid 22 (14)
Mucinous 12
Unclassiﬁed 25
Controls Endometrioma 36 37.5 +/-7.6
Uterine ﬁbroid 21(2) 47.2 +/-7.7
Ovarian cystoma 23 52.3 +/-15.0
Uterus cancer 16 159(16) 57.6 +/-11.2
Menstruation 19 36.2 +/-8.9
Healthy women 44(14) 46.9 +/-10.1
() Caucasian.
521M. Mikami et al. / Gynecologic Oncology 139 (2015) 520–528diagnosis [2]. Early-stage EOC has a nearly 90% 5-year survival rate
as opposed to less than 30% in advanced-stage disease, so develop-
ing a useful screening method is of utmost importance in EOC.
Among EOC patients those with clear cell carcinoma (OCCC) were
signiﬁcantly more likely to have FIGO Stage I disease than were
those with Serous adenocarcinoma (SAC) (48.5% vs. 16.6%). A
high recurrence rate was noted in those patients with Stage IC
CCC (37%), however, the survival rates for these patients were
lower than those for patients with SAC [3].
Various attempts have been made at ovarian cancer screening
following the identiﬁcation of the cancer antigen 125 (CA-125) as
a biomarker for ovarian cancer more than 30 years ago. These
have included CA-125 combined with transvaginal ultrasonogra-
phy [4]. and CA-125 combined with other biomarkers [5]. Howev-
er, the results of CA-125-based screening approaches for ovarian
cancer diagnosis have as of yet, not been proven to be of efﬁcacious.
In addition, numerous studies including proteomic and nucleic
acid–based analyses have been conducted to identify biomarkers
for ovarian cancer with little beneﬁt seen over the utility of
CA-125 [6]. A fundamental limitation of CA-125 in ovarian cancer
diagnosis is that it is often elevated in nonmalignant gynecologic
conditions such as in endometriosis.
Ovarian endometriosis is a prevalent gynecologic disease, partic-
ularly in young reproductive aged women [7]. Consequences of
endometriosis may include infertility, ectopic pregnancy, and chron-
ic pelvic pain. Due to the fact that endometriomas are commonly
seen in reproductive aged women, usual management includes
either conservative surgery or close observation in order to preserve
ovarian function. The most concerning issue surrounding the
management of endometriomas is that there is a risk of malignant
degeneration to OCCC, one of the more aggressive subtypes of ovar-
ian cancer [8].
Common strategies for the discovery of new cancer biomarkers,
include identiﬁcation of anomalous alternative mRNA splicing prod-
ucts of an expressed gene, as well as genes which are re-expressed
following silencing during normal differentiation. Although identiﬁ-
cation of sugar chain alterations produced by cancer cells represents
another strategy for biomarker discovery, the low productivity of an-
tibodies for the speciﬁc sugar chains, previously discovered sugar
chain markers are the “tip of the iceberg” of numerous cancer-
speciﬁc markers [9].
Dramatic improvements in mass spectrum (MS) technology in
sensitivity, resolution, throughput, and dynamic range have revo-
lutionized the approach to biomarker analysis in this decade.
With this novel technology, we investigated not only sugar chain
alterations but also the combination of protein and glycan changes.
However, direct exhaustive analysis of serum glycoproteins has
remained difﬁcult because of the numerous peaks in MS data
[10]. To solve this problem, highly efﬁcient and enriched strategiesto isolate glycopeptides with new MS data analyzing methods had
been required.
The aim of this study was to establish a novel technology to explore
new glycoprotein markers for EOC, and among them to ﬁnd a highly
speciﬁc marker for the early diagnosis of EOC that could overcome the
weaknesses of the current EOC markers.
2. Materials and methods
2.1. Patient samples (Table 1 and Table S1)
During the study period (2010–2014) total of 293 consecutive serum
samples were obtained at the time of ovarianmass detection and prior to
the initiation of any treatment. These included EOC patients (n = 134)
and a control group (n = 159). The mean age of EOC patients was 56.8
(SD ± 12.5). The ethnicity of the EOC group consisted of Asian (n =
120, 89.6%) and Caucasian (n= 14, 10.4%). The most common histologic
subtypes of EOC was OCCC (n = 45, 33.6%), followed by serous (n = 30,
22.4%), unclassiﬁed (n = 25, 18.7%), endometrioid (n = 22, 16.4%), and
mucinous adenocarcinoma (n = 12, 9.0%). The non-cancer control
group comprised both healthy women (n= 63) and women with gyne-
cologic diseases, including endometrioma which may also demonstrate
elevated CA125 levels (n = 96). Among 63 healthy women, there were
19 (30.2%) pre-menopausalwomen inwhomblood samplingwas obtain-
ed during the menstrual period, and the remaining 44 (69.8%) healthy
womenhad blood sampling outside of theirmenstrual periods (pre-men-
opausal n=24, post-menopausal n=11, and unknownmenstrual status
n = 9). Among 96 patients with gynecologic disease other than ovarian
cancer, there were 36 (37.5%) cases of endometrioma. The mean age of
the control group, stratiﬁed by diagnosis, included: endometrioma 37.5
(±7.6), uterine myomas 47.2 (±7.7), benign ovarian cyst 52.3 (±15.0),
uterine cancer 57.6 (±11.2), healthy menstruating women 36.2 (±8.9),
and healthy women without menstruation 46.9 (±10.1). In addition,
ﬂuid samples from the cystic component of EOC (n=8) and frombenign
ovarian tumor (n = 5) were also collected. Additional blood samples
were obtained 1 year after completion of the initial ovarian cancer treat-
ment for nine randomly selected EOC patients that demonstrated elevat-
ed A2160 levels at the initial diagnosis. All blood samples were collected
by venous puncture from patients before surgery and from healthy indi-
viduals at their ﬁrst hospital admission. Samples were centrifuged and
stored at−80 °C for further examination, with avoidance of repeated
freeze-thaw cycles.
2.2. Glycopeptide proﬁling and marker screening
The outline schema of the process is shown in Fig. 1A. The de-
tailed descriptions of the techniques are described in Supplemental
Appendix. Brieﬂy, after extracting serum glycoproteins and treat-
ment with proteases, glycopeptides were enriched by ﬁltration and
AAL lectin column chromatography, followed by liquid chromatog-
raphy mass spectrometry (LC-MS). The errors of peak intensity in
the raw MS data were corrected by internal glycopeptide standards,
and all peak areas were then normalized to those of one healthy
woman (HEA1433), which was set at one unit. The reason why we
chose HEA1433 for normalization was that MS proﬁle of HEA1433
showed typical normal healthy pattern among controls, and there
were enough sera as a normalizing standard. All processes were
monitored by utilization of QC (Quality Control) samples prepared
by pooling all patient and control sera. QCs were analyzed every 15
samples and if the values became abnormal, that batch including
the QC was reanalyzed.
2.3. Peptide sequencing and analysis of sugar chains
The outline schema of the process is shown in Figure S7. Glycans
were removed from the potential marker glycopeptide, and were
Fig. 1. Schema of gyloprotein proﬁling strategy and data mining (A) Glycopeptide proﬁling strategy is shown. After serum glycoproteins were treated with proteases, glycopep-
tides were enriched by ﬁltration and AAL lectin column chromatography, and then were analyzed by LC-MS. The position and area of each peak were calculated by our original
software. Then all peak areas were normalized to those of a healthy woman (HEA1433), which was set at one unit. A potential newmarker of epithelial ovarian cancer (EOC) was
identiﬁed through investigation of over 100,000 glycopeptide peaks by using t-test, mean fold change (MFC) analysis, and receiver-operator-characteristic (ROC) characteristics
analysis for comparison between the EOC and control groups. (B) Data Mining is shown. Glycopeptide A2160 was identiﬁed from among more than 100,000 glycopeptide peaks
by analysis with t-test (2517 peaks with P b 10−8 compared with controls), MFC analysis (193/2517 peaks with mean values ≥4 times those of controls), and ROC analysis (iden-
tifying the peak with the highest AUC among 193 peaks).
Fig. 2. Comparison of A2160 and CA-125 levels in diagnosing ovarian cancer (A–B) Box-whisker plots for A2160 and CA-125 levels in healthy subjects and various gynecological diseases
are shown. The cut-off value of A2160was set tomaximize the sensitivity and speciﬁcity, and was found to be 1.6 U/mL. Superiority of A2160 over CA-125was demonstrated by compar-
ison of the EOCgroup and the control group including patientswith falsely elevatedCA-125 level, especially in endometrioma. The range of CA-125values (1–10,000U/mL) inEOCpatients
was signiﬁcantlywider than that of A2160 values (1–50U/mL). EOC: epithelial ovarian cancer, HE: Healthywomen, EM: endometrioma,UF: uterineﬁbroid, UC: uterine cervical cancer, EC:
endometrial cancer, CY: ovarian cyst, ME: menstruation. (C–D) A2160 and CA-125 levels are shown for endometrioma, stages I–II OCCC and stage III-IV OCCC. Magnitude of statistical sig-
niﬁcance of A2160 between stages I–II OCCC and healthy subjects (P=0.001, t-test) was larger than that of CA-125 (P=0.02). (E) ROC curve analysis of A2160 and CA125 between stages
I–II OCCC (n = 27) and endometrioma (n= 36). AUC for A2160 (0.92, 95%CI 0.84–0.99) was markedly larger than AUC for CA-125 (0.67, 95%CI 0.53–0.81) in distinguishing OCCC from
endometrioma. (F–G) Interval changes of A2160 and CA125 levels in EOC patients before and one year after treatment are shown. Eight patients with elevated A2160 levels went into
remission after tumor resection, and A2160 levels paralleled with CA-125 level. There was one patient (T175) developed EOC recurrence: only A2160 level was elevated at recurrence,
and CA-125 levels did not show elevation.
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523M. Mikami et al. / Gynecologic Oncology 139 (2015) 520–528subjected to analysis by LC-MS/MS. The peptide fragment pattern
was assessed with MASCOT (Matrix Science, Boston, MA). Sugar
chain structures were determined by LC-MS analysis of marker gly-
copeptide fragments and by LC analysis of N-glycans released from
the glycopeptide.2.4. Essential glycan structure of the new marker
The outline schema of the process is shown in Figure S7. Serum
glycoproteins obtained from EOC patients (n = 19) and control sub-
jects (healthy women, n = 10; endometrioma, n = 19) were
524 M. Mikami et al. / Gynecologic Oncology 139 (2015) 520–528digested with speciﬁc enzymes to generate fragments of our new
marker glycopeptide with one glycan site on each peptide. These
fragments were analyzed by LC-MS, and AUCs were compared be-
tween the EOC and control subjects.
2.5. Statistical analysis
Continuous variables were expressed as mean (±standard deviation
[SD]) or median (range), and the statistical signiﬁcance was determined
by t-test or mean fold change (MFC) analysis, as appropriate. Categorical
variables were expressed with number (%). Diagnostic accuracy of bio-
markers for EOC over control counterparts was examined with ROC
curve analysis comparing AUCwith 95%CI. Based on the results, the cutoff
value of biomarker was determined and sensitivity, speciﬁcity, positive
predictive value (PPV), negative predictive value (NPV), and accuracy
for diagnosing EOCorOCCOover control groupwere calculated. All statis-
tical analyses were two-tailed, and P b 0.05 was considered as statistical
signiﬁcance. Statistical Package for the Social Sciences (SPSS, version
17.0, Chicago, IL, USA) and our original statistical software were used
for the analysis.
2.6. Study approval
Institutional Review Board (IRB) approval was obtained at Tokai
University (IRB registration number, 09R-082) andMitsubishi Chemical
Group Science and Technology Research Center, Inc. (IRB registration
number, 090,819–1) for the use of patient's clinical information and
serum/tumor samples. Upon obtaining these master IRB approvals, the
following participating institutions obtained the IRB for the patient ac-
crual: Tokai University Hospital (Kanagawa, Japan), the Leading Project
for Personalized Medicine of the Ministry of Education, Culture, Sports,
Science and Technology (Tokyo, Japan), Kanagawa Cancer Research
and Information Association (Kanagawa, Japan), Sho Hospital (Tokyo,
Japan), SOIKEN (Osaka Japan), and ProteoGenex, Inc.(California,
America). Signed informed consentswere obtained fromall participants
in the study.
3. Results
3.1. Glycopeptide proﬁling and screening for candidate markers
As a potential EOC marker, Glycopeptide A2160 was identiﬁed by
screening over 100,000 glycopeptide peaks using the t-test (2517
peaks had P b 10−8 compared with controls), MFC analysis (193/
2517 peaks had mean values ≥4 times that of controls), and
receiver-operator-characteristics (ROC) analysis (identifying one
peak [A2160] with the highest area-under-curve [AUC] among 193
peaks, Fig. 1A-B). Prior to this study, we conducted a validation of
this method. The differences of inter-day or intra-day reproducibility
(CV%) of the results of the assay were within 20%. Similarly, the
differences of error for the assay results between operators or labs
were also within 20%.
3.2. Diagnostic utility for EOC: A2160 versus CA-125
After A2160 was identiﬁed as the most potent biomarker for EOC,
the diagnostic accuracy of A2160 was determined by comparing it to
CA-125, a traditional biomarker for EOC. First, ROC curve analysis was
performed comparing EOC patients (n = 134) to healthy subjects not
currently on their menstrual period (n = 44). Based on the results,
the cutoff value of A2160 to maximize the sensitivity and speciﬁcityFig. 3. Identiﬁcation and sequencing of A2160 (A) Peptide sequence analysis and identiﬁcation
glycans) coincided with the alpha-chain of complement 4 binding protein (C4BP) from position
sugar chains. (B) A2160 glycopeptide analysis and proposed structure are shown. Themolecula
sugar chains binding to Asn 506 and 528 were A3G3S3F and A2G2S2, respectively.for diagnosing EOC was set as 1.6 U/mL. With this cutoff value for
A2160, there were 112 (84%) cases of EOC above the value. Diagnostic
utility of A2160 for EOC over healthy control was: sensitivity 84%, spec-
iﬁcity 82%, positive predictive value (PPV) 93%, negative predictive
value (NPV) 62%, and accuracy 83%, respectively. In the same compari-
son, elevated CA-125 (N35 IU/L) was seen in 105 (78.4%) cases of EOC,
and the diagnostic utility of CA-125 was: sensitivity 78%, speciﬁcity
100%, PPV 100%, NPV 60%, and accuracy 84%, respectively (Those perfor-
mances with 50 or 200 IU/L of CA-125 cutoff were shown in Table S2).
Next, serum A2160 and CA-125 levels were plotted across the various
disease types included EOC, other gynecologic conditions, and healthy
women (Fig. 2A-B). The results showed that diagnostic utility of
distinguishing EOC from endometrioma (plotted as EM) was superior
to that of CA-125.
ROC curve analysis for A2160 and CA-125 was then performed
comparing the EOC group and various subtypes of the control
group (Table S3). Among the 7 comparisons between A2160 and
CA-125, AUC of A2160 was superior or comparable in the majority
of comparisons. The most meaningful difference of AUCs between
A2160 and CA-125 existed in the comparison of EOC over
endometrioma: A2160, AUC 0.92 (95% conﬁdence interval [CI]
0.88–0.96, P b 10−15); and CA-125, AUC 0.77 (95% CI 0.70–0.84,
P b 10−6). Of note, among the subtypes of the control group,
endometrioma had the highest median CA-125 level with the near-
ly half of endometrioma cases having abnormally elevated CA-125
values higher than 35 IU/L (Fig. 2B). A2160 levels between EOC
and healthy subjects were compared across ethnicity groups
(Figure S1). Both Asian and Caucasian groups showed similar
trends and EOC patients had signiﬁcantly elevated A2160 com-
pared to healthy controls. Across the histologic subtypes of EOC,
the average level of serous adenocarcinoma patients (7.5 U/mL)
was little higher than that of the other EOCs (4.7 U/mL) patients
(P b 0.05), however, A2160 levels were similarly elevated when
compared to healthy and endometrioma subjects (Figure S2).
A2160 levels obtained from the cystic ﬂuid of ovarian tumors
were further compared between EOC (n = 8) and benign ovarian
tumors (n = 5). The results showed that A2160 levels were higher
in EOC compared to benign ovarian tumors (Figure S3).
This study speciﬁcally examined the diagnostic accuracy of A2160
and CA-125 for early-stage OCCC (stages I–II, n = 27) compared to
endometriomas (n = 36, Fig. 2C-D). Both A2160 and CA-125 levels
were statistically signiﬁcantly higher in women with OCCC than in
women with endometriomas; however, the magnitude of statistical
signiﬁcance was larger with A2160 as compared to CA-125 (P =
0.001 versus P=0.02). When ROC curves were constructed compar-
ing stages I–II OCCC to endometrioma, the diagnostic accuracy for
A2160 (AUC 0.92, 95%CI 0.83–0.99) was clinically meaningfully
higher than that of CA-125 (AUC 0.67, 95%CI 0.53–0.81, Fig. 2E).
With a cutoff value of 1.6 U/mL, the diagnostic utility of A2160 for
stage I-IV OCCC over endometrioma was: sensitivity 87%, speciﬁcity
94%, PPV 95%, NPV 85%, and accuracy 85%, respectively. With a cutoff
value of 35 IU/L, diagnostic utility of CA-125 for stage I-IV OCCC over
endometrioma was: sensitivity 71%, speciﬁcity 50%, PPV 64%, NPV
58%, and accuracy 62%, respectively. PPV of A2160 to diagnose
OCCC versus endometrioma (95%) was markedly higher than that
of CA-125 (64%). The PPV and NPV of A2160 were also higher than
those of CA-125 when the cutoff value of CA-125 was changed to
50 IU/L or 200 IU/L (Table S2).
The utility of A2160 as a surveillance maker for EOC progression
was examined (Fig. 2F–G). At the time of data analysis, nine EOC
patients with elevated A2160 levels at the time of the initialof A2160 are shown. TheMS/MS fragmentation pattern of A2160 peptide (after removing
s 499 to 529 of the amino acid sequence. Asn (N)was changed to Asp (D) by hydrolysis of
r weights of the glycopeptide fragments (detected as triply charged ions) revealed that the
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Fig. 4.Comparison of fully versus partially sialylated alpha-chain of C4BPArea-under-curves (AUCs) of various glycans at the 506 and 528 sites of the C4BP alpha-chain in the serumof EOC
(n = 19) and control subjects (healthy women n = 10, and endometrioma n = 19) were examined. (A) ROC curves of tri-antennary glycans on Asn 506 in the C4BP alpha-chain are
shown. Fully-sialylated glycopeptides (binding 3 sialic acids) showed a signiﬁcantly higher AUC than partially-sialylated glycans. (B) Receiver-operator-characteristic (ROC) curves of
bi-antennary glycans on Asn 528 in the C4BP alpha-chain are shown. Fully-sialylated glycopeptides (binding 2 sialic acids) showed a markedly higher AUC than monosialylated glycans.
(C) AUC values of each glycopeptide derived from the C4BP alpha-chain are shown. Comparing AUCs between epithelial ovarian cancer patients and the control group revealed that gly-
copeptides with fully-sialylated glycans showed signiﬁcantly higher AUCs than those with partially-sialylated glycans. This trend was observed regardless of the binding sites and fucose
binding. Error bars indicate 95% conﬁdence interval of AUC. Red diamond-shape: sialic acids, Gray triangle-shape: fucose, A2G2: bi-antennary N-glycan, A3G3: tri-antennary N-glycan,
A2G2F: bi-antennary N-glycan with one fucose, A3G3F: tri-antennary N-glycan with one fucose.
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ative follow-up were randomly chosen. Of those, there were eight
(88.8%) patients who were in remission after one year from treat-
ment, and all except for one patient (T15) had markedly decreased
A2160 levels compared to pre-treatment levels. There was one pa-
tient (T175) who developed disease recurrence. In this case, serum
A2160 level was signiﬁcantly elevated at the time of recurrence
without elevation of CA-125.
3.3. Combination assay of A2160 and CA125
There was a weak correlation observed between A2160 and CA125
(r = 0.60), however, the relationship was complementary, and CA125
negative (less than 35 UI/mL) patients could be judged as positive
based on A2160 levels. Furthermore the combination with A2160 and
CA125, which is calculated by the following equation, showed much
higher AUC (0.93) compared to solo A2160 or CA125. (The factorswere optimized by Microsoft Excel Solver). Combination index =
Log10(CEA) × 0.3 + Log10(A2160) × 0.7, The sensitivity and speciﬁcity
of the combination index became 81% and 95% respectively when the
cut-off was deﬁned as 0.70 U/mL (Figure S4).
3.4. Peptide and glycan structural analysis of A2160
The MS/MS fragmentation pattern of A2160 peptide coincided
with the alpha-chain of complement 4 binding protein (C4BP), and
it was determined to match positions 499 to 529 of the amino acid
sequence (Fig. 3A). The peptide had 2 N-glycan binding sites
(Asn506 and Asn528). The peptide was bound to 2 glycans with 11
hexoses, 9 HexNAcs, 5 N-acetyl neuraminic acids, and 1 fucose,
based on the molecular weight difference between before and after
removing the N-glycans from A2160 glycopeptide. Judging from
the molecular weight of the A2160 fragment glycopeptides separat-
ed at the middle of 2 glycan sites, the proposed glycan structures
527M. Mikami et al. / Gynecologic Oncology 139 (2015) 520–528were determined to be A3G3S3F and A2G2S2, which were bound to
Asn 506 and 528, respectively (Fig. 3B).
3.5. Key alteration of glycan chains in the C4BP alpha-chain
Comparison of AUC values between the EOCpatients and the control
group revealed that glycopeptides with fully-sialylated glycans showed
signiﬁcantly higher AUC values compared to glycopeptides with
partially-sialylated glycans (Figs. 4A-B and S5). This difference was ob-
served regardless of the binding site (Asn506 or 528) or fucose binding
(Fig. 4C). The difference between full and partial sialylationwas not sig-
niﬁcant in other proteins like alpha-1-acid glycoprotein (Figure S6). Col-
lectively, these results suggest that the fully-sialylated alpha-chain of
C4-binding protein is a novel biomarker for EOC, and this is especially
potent in distinguish OCCC from endometrioma when compared to
CA-125.
4. Discussion
Key ﬁndings of our study were that A2160 is a potentially valuable
biomarker of EOC and that A2160 can be especially useful in
distinguishing early-stage OCCC from endometriomas. However, the
true predictive value of A2160 would have to be subjected to prospec-
tive analysis. Several of the salient topics merit further discussion.
Endometrioma is a form of endometriosis deﬁned as the presence of
ectopic endometrial tissue in the ovary. Overall, endometriosis can be
seen in 6–10% of reproductive aged women (7). Recent epidemiologic
and genomic studies have shown that endometrioma can be associated
with an increased risk of future development of OCCC particularly in
womenwith a long-stang history of endometriosis [11–12]. For this rea-
son, women with endometriomas beneﬁt from close observation for
long-termmonitoring. Becase CA-125, a traditional biomarker for ovar-
ian cancer diagnosis, can be abnormally elevated in more than half of
endometriomas (Fig. 2B and Table S2), the novel biomaker A2160
could satisfy an unmet need in allowing proper diagnosis of ovarian
cancer in women with endometriosis and a pelvic mass. Our study is
the ﬁrst to demonstrate a higher diagnostic utility of A2160 than
CA-125 to identify stages I–II OCCC over endometrioma, indicating
that there is a clinical implication of A2160 for early detection of ovarian
cancer (Fig. 2E).
Our data speculate that A2160 is likely produced from the ovarian
cancer cells. A subset analysis of our clinical samples showed that the
ﬂuid aspirated from cystic counterparts of ovarian cancer had a trend
of higher A2160 level compared to the ﬂuid obtained from benign ovar-
ian cysts (Figure S3). This is indeed supported by the results of a preclin-
ical study by others demonstrating an expression of alpha-chain of C4BP
in ovarian cancer cell lines whereas the normal ovarian tissue expresses
beta-chain of C4BP [13–14]. One direction of interest may be therefore
to examine the survival impact of elevatedA2160 as a predictivemarker
of disease progression. In addition, a group of our patients with long-
term follow-up showed that A2160 paralleled to the disease status, im-
plying that A2160 can be a possible diseasemonitoringmarker after the
treatment (Fig. 2F). There was one case (T175) of recurrence with ele-
vated A2160 level without elevation of CA-125. Further study will be
needed to answer if A2160 is superior to CA-125 to detect ovarian can-
cer recurrence.
The role of C4BP in cancer biology remains incompletely understood.
A2160 is a component of C4BP that is a large glycoprotein (500 kDa)
mainly produced in the liver [14]. The main structure of the C4BP mol-
ecule in the blood circulating system consists of 7 identical alpha-
chains and additional 1 unique beta-chain (Fig. 3B). Functionally, C4BP
is amember of the complement cascade, inwhich it acts as an inhibitory
player. That is, C4BP suppresses the overactivation of the complement
system as part of the process of innate immunity. This is of a particular
interest in a view of cancer immunity as it is speculated that ovarian
cancer cells may produce A2160 to allow the cell to escape the hostinnate immune response via C4BP's inhibitory function of the mem-
brane attack complex (MAC) in the complement pathway.
A possiblemechanismbywhich the ovarian cancer cell escapes from
host immunity is via the A2160-driven protection, whichmerits further
speculation. C4BP is known to bind strongly to ovarian cancer cells as
shown in an in-vitro study, and this binding capacity is based on the
electric balance regulation between C4BP and the cancer cell [15]. Our
results showed that the fully-sialylated alpha-chain of C4BP was more
potent in diagnosing ovarian cancer as compared to the partially-
sialylated counterpart (Fig. 4A–C). Because sialic acid is a negatively
charged molecule, it is reasonably theorized that the fully-charged
sialylated form has larger afﬁnity for ovarian cancer cells than the
partially-sialylated formof alpha-chain of C4BP. As a consequence, ovar-
ian cancer cells covered by A2160, the fully-sialylated form, may be
more protected from the complement-induced tumor immune system.
Detection of early ovarian cancer has been challenging given that very
few qualitative and quantitative circulating biomarkers have been avail-
able. In this setting, full-sialylation of the C4BP alpha-chain at sites 506
and 528, is a better candidate for the early detection of ovarian cancer,
as compared to partial-sialylation, as full-sialylation is associatedwith de-
layed liver metabolism via the hepatocyte asialoglycoprotein receptor,
and results in a prolonged half-life in the blood circulation [15–17].
Sustained blood levels of fully-sialylated A2160, therefore, enables us to
detect OCCC in early-stage more readily than does CA-125 (Fig. 2C–D).
A2160 was identiﬁed by the extensive glycopeptide analysis in this
study that required us to develop a novel methodological approach in
mass spectrum technology. During this exploration of ovarian cancer
biomarkers, we also examined several other candidates, in addition to
A2160, for glycan sialylation that demonstrated substantial AUC values
for EOCmarkers (Figure S6). Notably, we found that there was no other
marker whose speciﬁcity was affected by the level of sialylation other
than A2160. In the past, increased fucosylation has been found in the
analysis of glycopeptides of haptogloblin in pancreatic cancer [18]. An-
other study developed a comprehensivemethod for serumglycoprotein
analysis by combining lectin arrays with mass spectrometry [19]. How-
ever, their technologies only targeted certain glycoproteins and did not
screen all the peptides with bound sugar chains. The main difﬁculty of
performing comprehensive glycopeptide proﬁling by using MS is the
complexity of analyzing a huge number of peaks [9]. The estimated
number of glycopeptide patterns can be more than 100,000 when
serum protein (more than 1000) and sugar chains (more than 100)
are combined together, and it has been extremely difﬁcult to analyze
such mega data. We developed highly efﬁcient enrichment strategies
for glycopeptides by using a special ﬁltration and a lectin column
(manuscript in preparation), as well as novel software to analyze MS
mathematically and macroscopically by using speciﬁc internal stan-
dards without labeling (manuscript in preparation).
In summary, the fully-sialylated alpha-chain of C4-binding protein,
A2160, is a newly identiﬁed biomarker for ovarian cancer. The potential
role of A2160 for both diagnostic and therapeutic implications could
signiﬁcantly impact the care of women with pelvic masses at risk of
ovarian cancer. That is, A2160 can be valuable for early diagnosis and
monitoring of ovarian cancer; and understanding the function of
A2160 has therapeutic implications in terms of overcoming cancer im-
mune resistance. Validation and further studies are warranted.
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